MA30038B1 - Glycosylation d'anticorps dans la region variable - Google Patents

Glycosylation d'anticorps dans la region variable

Info

Publication number
MA30038B1
MA30038B1 MA31014A MA31014A MA30038B1 MA 30038 B1 MA30038 B1 MA 30038B1 MA 31014 A MA31014 A MA 31014A MA 31014 A MA31014 A MA 31014A MA 30038 B1 MA30038 B1 MA 30038B1
Authority
MA
Morocco
Prior art keywords
antibody
glycosylated
variable region
asn
heavy chain
Prior art date
Application number
MA31014A
Other languages
English (en)
Inventor
Hansruedi Loetscher
Walter Huber
Diana Schuhbauer
Karl Weyer
Manfred Brockhaus
Bernd Bohrmann
Hans Koll
Andreas Schaubmar
Kurt Lang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30038B1 publication Critical patent/MA30038B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une préparation à base de molécule d'anticorps purifiée caractérisée en ce qu'au moins un site de liaison à l'antigène comprend une asparagine (Asn) glycosylée dans la région variable de la chaîne lourde (Vu). Plus spécifiquement, une composition pharmaceutique et une composition diagnostique comprenant ladite molécule d'anticorps et les mélanges d'anticorps sont mis à disposition, qui est/sont capable(s) de reconnaître spécifiquement le peptide (3-A4/A(beta)4. La présente invention concerne en particulier un mélange d'anticorps comprenant un ou deux sites de liaison à l'antigène glycosylé avec une asparagine (Asn) glycosylée dans la région variable de la chaîne lourde, c'est-à-dire des mélanges d'isoformes d'anticorps qui comprennent une Asn glycosylée dans la région variable de la chaîne lourde (VH). Des compositions ou préparations d'anticorps comprenant les isoformes d'anticorps spécifiquement glycosylés sont également décrites. En outre, les utilisations pharmaceutique et diagnostique pour ces anticorps sont mises à disposition. Les isoformes d'anticorps peuvent par exemple être utilisées dans l'intervention pharmaceutique lors d'une amyloïdogenèse ou de la formation de plaques amyloïdes et/ou dans le diagnostic de celles-ci.
MA31014A 2005-12-12 2008-06-09 Glycosylation d'anticorps dans la region variable MA30038B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05027090 2005-12-12

Publications (1)

Publication Number Publication Date
MA30038B1 true MA30038B1 (fr) 2008-12-01

Family

ID=37745986

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31014A MA30038B1 (fr) 2005-12-12 2008-06-09 Glycosylation d'anticorps dans la region variable

Country Status (33)

Country Link
US (2) US8906370B2 (fr)
EP (2) EP2377886A1 (fr)
JP (1) JP5145241B2 (fr)
KR (2) KR20080077132A (fr)
CN (2) CN101351476B (fr)
AR (1) AR057233A1 (fr)
AT (1) ATE517923T1 (fr)
AU (1) AU2006326301B2 (fr)
BR (1) BRPI0619605B8 (fr)
CA (1) CA2632828C (fr)
CR (1) CR10000A (fr)
CY (1) CY1114783T1 (fr)
DK (1) DK1960428T3 (fr)
DO (1) DOP2006000278A (fr)
EC (1) ECSP088524A (fr)
ES (1) ES2368591T3 (fr)
IL (1) IL191004A (fr)
JO (1) JO2824B1 (fr)
MA (1) MA30038B1 (fr)
MY (1) MY155286A (fr)
NO (1) NO346105B1 (fr)
NZ (1) NZ568241A (fr)
PE (3) PE20100684A1 (fr)
PL (1) PL1960428T3 (fr)
PT (1) PT1960428E (fr)
RS (1) RS52004B (fr)
RU (1) RU2438706C2 (fr)
SI (1) SI1960428T1 (fr)
TW (1) TWI382990B (fr)
UA (1) UA99097C2 (fr)
UY (1) UY30003A1 (fr)
WO (1) WO2007068429A1 (fr)
ZA (1) ZA200805038B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CA2632828C (fr) * 2005-12-12 2012-07-10 F. Hoffmann-La Roche Ag Anticorps contre la beta-amyloide ayant subi une glycosylation dans la region variable
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
EP2124952A2 (fr) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Méthode de traitement d'amyloïdoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2689125C (fr) * 2007-06-29 2015-10-20 Ulrich Goepfert Mutant a chaine lourde conduisant a une production amelioree d'immunoglobuline
EP2185591B1 (fr) * 2007-08-20 2014-05-14 Glaxo Group Limited Procédé de production
EP2586795B1 (fr) 2007-10-05 2018-05-16 Genentech, Inc. Utilisation d'anticorps anti-beta amyloide aux maladies oculaires
ES2511844T3 (es) * 2007-12-21 2014-10-23 F. Hoffmann-La Roche Ag Formulación de anticuerpo
CN102076865B (zh) * 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
US20140213465A1 (en) * 2011-12-02 2014-07-31 Plaxgen, Inc. Plaque array methods and compositions for forming and detecting plaques
WO2010127069A1 (fr) * 2009-04-29 2010-11-04 Schering Corporation Purification d'anticorps
EP2519537A4 (fr) * 2009-12-29 2013-07-10 Reddys Lab Ltd Dr Purification des protéines
US8337845B2 (en) 2010-03-03 2012-12-25 Boehringer Ingelheim International Gmbh A-beta binding polypeptides
EP2558494B1 (fr) 2010-04-15 2018-05-23 AbbVie Inc. Protéines de liaison à la bêta amyloïde
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
WO2012142301A2 (fr) 2011-04-12 2012-10-18 Quanterix Corporation Procédé de détermination d'un protocole de traitement et/ou d'un pronostic de rétablissement d'un patient à la suite d'un traumatisme cérébral
CA2853112C (fr) * 2011-10-25 2018-08-21 Onclave Therapeutics Limited Formulations d'anticorps et procedes correspondants
AU2013229613B2 (en) 2012-03-08 2015-07-30 F. Hoffmann-La Roche Ag Abeta antibody formulation
RU2711552C2 (ru) * 2012-08-29 2020-01-17 Ф. Хоффманн-Ля Рош Аг Шаттл для гематоэнцефалического барьера
CN102998454A (zh) * 2012-12-11 2013-03-27 华中师范大学 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
TWI630215B (zh) 2012-12-18 2018-07-21 美國洛克菲勒大學 用於ｈｉｖ預防及治療的醣修飾抗ｃｄ４抗體
AU2014217561B2 (en) 2013-02-13 2018-11-15 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Highly galactosylated anti-TNF-alpha antibodies and uses thereof
JP6169885B2 (ja) 2013-05-07 2017-07-26 株式会社日立製作所 精製装置及び精製方法
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
EP3683232A1 (fr) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Procédés et compositions comprenant des polypeptides recombinants purifiés
CN110302394A (zh) 2013-11-22 2019-10-08 国立大学法人东京大学 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (fr) 2014-04-29 2015-11-05 Affiris Ag Traitement et prévention de la maladie d'alzheimer
CR20210429A (es) 2015-06-24 2021-09-24 Hoffmann La Roche ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
ES2877532T3 (es) * 2015-08-21 2021-11-17 Hoffmann La Roche Procedimiento para la reducción de proteínas de célula huésped en cromatografía de afinidad
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
EP3155958B1 (fr) * 2015-10-16 2021-11-17 Roche Diabetes Care GmbH Procédé pour faire fonctionner un système et système
AU2016354688B2 (en) 2015-11-09 2021-12-16 The University Of British Columbia Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
EP3374379A4 (fr) 2015-11-09 2019-05-15 The University Of British Columbia Épitopes n-terminaux dans la bêta-amyloïde et anticorps conformationnellement sélectifs associés
JP7452829B2 (ja) 2015-11-09 2024-03-19 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータのエピトープおよびそれに対する抗体
US10792477B2 (en) * 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
EP3427183A1 (fr) * 2016-03-10 2019-01-16 Genomic Vision Procédé de détection et d'analyse de signal curviligne, et plate-forme associée
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
ES3038711T3 (en) * 2017-05-30 2025-10-14 Morinaga Milk Industry Co Ltd Acetic acid and/or an acetic acid salt for use in the treatment of alzheimer-type dementia
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CA3070085A1 (fr) 2017-07-18 2019-01-24 The University Of British Columbia Anticorps anti-beta-amyloide
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
EP3778875A1 (fr) 2019-08-14 2021-02-17 MaxiVax SA Lignées de cellules myoblastes immortalisées et leurs utilisations
WO2022020680A1 (fr) 2020-07-23 2022-01-27 Othair Prothena Limited Anticorps anti-abêta
CN116615231A (zh) * 2020-11-16 2023-08-18 豪夫迈·罗氏有限公司 Fab高甘露糖糖型
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (fr) 2021-05-24 2022-12-01 Eli Lilly And Company Anticorps anti-amyloïde bêta et leurs utilisations
CN114720543B (zh) * 2022-04-06 2026-02-24 苏州大学 一种基于固相糖蛋白t抗原糖肽富集和酶切分析的方法
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
TW202434629A (zh) 2023-01-26 2024-09-01 愛爾蘭商歐薩爾普羅席納有限公司 以抗類澱粉β (ABETA)抗體治療神經病症之方法
CN121693516A (zh) 2023-08-09 2026-03-17 豪夫迈·罗氏有限公司 单特异性和多特异性抗trem2抗体、其方法及用途
KR20260051039A (ko) 2023-08-09 2026-04-15 에프. 호프만-라 로슈 아게 항-a-베타 단백질 항체, 이의 제조 방법 및 용도
CN117783359B (zh) * 2023-12-28 2024-12-31 中国计量科学研究院 一种基于串联质谱的转基因蛋白多靶同检方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1339014C (fr) 1987-10-08 1997-03-25 Ronald E. Majocha Anticorps pour peptide a4-amyloide
JP2780507B2 (ja) * 1991-03-29 1998-07-30 松下電器産業株式会社 内燃機関用フィルタ再生装置
US5955317A (en) * 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP0683234B2 (fr) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
AU5976996A (en) * 1995-06-06 1996-12-24 Stemcell Therapeutics L.L.C. Glycoprotein gp105 on bl3 hematopoietic stem cells
ATE219517T1 (de) 1995-08-18 2002-07-15 Morphosys Ag Protein-/(poly)peptidbibliotheken
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2290023T3 (es) * 1999-03-04 2008-02-16 Praecis Pharmaceuticals Incorporated Moduladores de la agregacion del peptido beta-amiloide que comprenden d-aminoacidos.
ES2312348T3 (es) 1999-06-16 2009-03-01 Boston Biomedical Research Institute Control inmunologico de niveles de beta-amiloide in vivo.
AU6722300A (en) 1999-08-31 2001-03-26 Ramot University Authority For Applied Research And Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
NZ540564A (en) 1999-11-29 2007-04-27 Neurochem Int Ltd Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
EP1125905A1 (fr) 2000-02-16 2001-08-22 Pepscan Systems B.V. Synthèse de segments
IL151378A0 (en) 2000-02-24 2003-04-10 Univ Washington Humanized antibodies that sequester amyloid beta peptide
CA2313828A1 (fr) 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Modification post-traduction de .beta.-secretase(bace) : les domaines cytosolyques pro- et transmembranaires ont des effets sur l'activite cellulaire et sur la production de la proteine .beta.amyloide
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ATE385811T1 (de) 2000-12-19 2008-03-15 Palatin Technologies Inc Identifizierung zielgerichteter faltungsstellen in peptiden und proteinen
ES2312569T3 (es) 2001-04-30 2009-03-01 Eli Lilly And Company Anticuerpos humanizados.
ES2318006T3 (es) 2001-04-30 2009-05-01 Eli Lilly And Company Anticuerpos humanizados que reconocen el peptido beta-amiloide.
US7771722B2 (en) * 2001-08-17 2010-08-10 Eli Lilly And Company Assay method for alzheimer's disease
CA2451998A1 (fr) * 2001-08-17 2003-02-27 Eli Lilly And Company Anticorps anti-$g(a)$g(b)
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1633786A4 (fr) 2002-10-09 2007-07-25 Rinat Neuroscience Corp Methodes de traitement de la maladie d'alzheimer au moyen d'anticorps diriges contre le peptide g(b)-amyloide et compositions les comprenant
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2632828C (fr) * 2005-12-12 2012-07-10 F. Hoffmann-La Roche Ag Anticorps contre la beta-amyloide ayant subi une glycosylation dans la region variable
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂

Also Published As

Publication number Publication date
SI1960428T1 (sl) 2011-10-28
DK1960428T3 (da) 2011-08-22
BRPI0619605A2 (pt) 2011-10-11
TWI382990B (zh) 2013-01-21
ZA200805038B (en) 2009-06-24
RU2008128138A (ru) 2010-01-20
AR057233A1 (es) 2007-11-21
NO20082874L (no) 2008-08-28
US9272031B2 (en) 2016-03-01
US20150165022A1 (en) 2015-06-18
AU2006326301B2 (en) 2011-04-21
TW200736273A (en) 2007-10-01
CR10000A (es) 2008-07-29
MY155286A (en) 2015-09-30
US8906370B2 (en) 2014-12-09
UY30003A1 (es) 2007-08-31
BRPI0619605B8 (pt) 2021-05-25
DOP2006000278A (es) 2007-07-15
PE20100684A1 (es) 2010-10-04
NO346105B1 (no) 2022-02-21
JP2009520691A (ja) 2009-05-28
KR20120089483A (ko) 2012-08-10
WO2007068429A1 (fr) 2007-06-21
US20090252724A1 (en) 2009-10-08
CA2632828C (fr) 2012-07-10
CN101351476A (zh) 2009-01-21
CN101351476B (zh) 2013-04-03
ECSP088524A (es) 2008-07-30
CY1114783T1 (el) 2016-12-14
PL1960428T3 (pl) 2012-02-29
CN102659943A (zh) 2012-09-12
ES2368591T3 (es) 2011-11-18
RU2438706C2 (ru) 2012-01-10
BRPI0619605A8 (pt) 2019-01-15
CA2632828A1 (fr) 2007-06-21
PE20071002A1 (es) 2007-11-19
CN102659943B (zh) 2015-07-01
EP1960428A1 (fr) 2008-08-27
RS52004B (sr) 2012-04-30
AU2006326301A1 (en) 2007-06-21
UA99097C2 (ru) 2012-07-25
ATE517923T1 (de) 2011-08-15
IL191004A (en) 2013-08-29
HK1176075A1 (en) 2013-07-19
KR20080077132A (ko) 2008-08-21
HK1130066A1 (en) 2009-12-18
PE20100748A1 (es) 2010-11-12
EP2377886A1 (fr) 2011-10-19
PT1960428E (pt) 2011-10-07
JO2824B1 (en) 2014-09-15
KR101401159B1 (ko) 2014-05-29
EP1960428B1 (fr) 2011-07-27
BRPI0619605B1 (pt) 2019-08-13
JP5145241B2 (ja) 2013-02-13
NZ568241A (en) 2011-08-26

Similar Documents

Publication Publication Date Title
UA99097C2 (ru) Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок
MA27773A1 (fr) Preparations d'anticorps et de proteines a forte concentration
MA29606B1 (fr) Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol
TNSN07423A1 (fr) Composition pharmaceutique comprenant un agent antiparasitaire, et un actif choisi parmi le carveol, le thymol, l'eugenol, le borneol, le carvacrol, l 'alpha-ionone ou le beta-ionone
EP1111053A3 (fr) Fragment peptidique de la protéine g du virus respiratoire syncytial, agent immunogène, composition pharmaceutique le contentant et procédé de préparation
CA2176840A1 (fr) Association d'un compose a activite anti-microbienne et d'un monoalkylether de glycerol
MA30156B1 (fr) Immunoglobulines
MA27952A1 (fr) Anticorps neutralisants anti-ngf humains utilises comme inhibiteurs selectifs de la voie de ngf
WO2002086443A8 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
MA29630B1 (fr) Ingredient pharmaceutique actif du cannabinoide pour des formes de dosage ameliorees
TNSN07425A1 (fr) Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol,l'eugenol, le thymol, le borneol, le carvacrol, et les ionones alpha-et-beta-.
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
WO2006020580A3 (fr) Variants de polypeptides synthetiques hyperglycosyles resistants a la protease, formulations orales et leurs procedes d'utilisation
MA30689B1 (fr) Derives de leptomycine
MY138289A (en) Pharmaceutical compositions
EP1039548A3 (fr) Composant semi-conducteur commandé par effet de champ
EP1132463A3 (fr) Composition cosmétique contenant un antagoniste des récepteurs du neuropeptide Y
MA27908A1 (fr) Agents therapeutiques utiles pour le traitement de la douleur
MA31796B1 (fr) Composes organiques
MA29723B1 (fr) Composes
CA2296711A1 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
MA28160A1 (fr) Antagonistes du recepteur de la bradykinine b1
CA2072350A1 (fr) Polypeptides impliques dans l'expression de la resistance aux antibiotiques glycopeptidiques
WO2002007676A3 (fr) Composés à affinité pour le récepteur du facteur de stimulation des colonies de granulocytes (g-csfr)
FR3086946B1 (fr) Procede ameliore pour la fabrication de polyamides transparents